Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib for ACPA-positive Rheumatoid Arthritis
NCT05502731Phase 4Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Frequency of ACPA-expressing B cells at 24 weeks. Status: unknown.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05502731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502731.